A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

NCT01311050 · clinicaltrials.gov ↗

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Sponsor

King Faisal Specialist Hospital & Research Center